ID   S22A1_RAT               Reviewed;         556 AA.
AC   Q63089; O35882; Q6AYW1;
DT   20-MAY-2008, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   02-OCT-2024, entry version 163.
DE   RecName: Full=Solute carrier family 22 member 1 {ECO:0000303|PubMed:11408531};
DE   AltName: Full=Organic cation transporter 1 {ECO:0000303|PubMed:8955087};
DE            Short=rOCT1 {ECO:0000303|PubMed:8955087};
GN   Name=Slc22a1 {ECO:0000312|RGD:3224}; Synonyms=Oct1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR LOCATION, AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=7990927; DOI=10.1038/372549a0;
RA   Gruendemann D., Gorboulev V., Gambaryan S., Veyhl M., Koepsell H.;
RT   "Drug excretion mediated by a new prototype of polyspecific transporter.";
RL   Nature 372:549-552(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), FUNCTION (ISOFORM 2), TISSUE
RP   SPECIFICITY, AND TISSUE SPECIFICITY (ISOFORM 2).
RC   STRAIN=Sprague-Dawley; TISSUE=Kidney;
RX   PubMed=9195965; DOI=10.1074/jbc.272.26.16548;
RA   Zhang L., Dresser M.J., Chun J.K., Babbitt P.C., Giacomini K.M.;
RT   "Cloning and functional characterization of a rat renal organic cation
RT   transporter isoform (rOCT1A).";
RL   J. Biol. Chem. 272:16548-16554(1997).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Kidney;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   MISCELLANEOUS.
RX   PubMed=8955087; DOI=10.1074/jbc.271.51.32599;
RA   Busch A.E., Quester S., Ulzheimer J.C., Waldegger S., Gorboulev V.,
RA   Arndt P., Lang F., Koepsell H.;
RT   "Electrogenic properties and substrate specificity of the polyspecific rat
RT   cation transporter rOCT1.";
RL   J. Biol. Chem. 271:32599-32604(1996).
RN   [5]
RP   FUNCTION.
RX   PubMed=9405386; DOI=10.1074/jbc.272.51.31953;
RA   Nagel G., Volk C., Friedrich T., Ulzheimer J.C., Bamberg E., Koepsell H.;
RT   "A reevaluation of substrate specificity of the rat cation transporter
RT   rOCT1.";
RL   J. Biol. Chem. 272:31953-31956(1997).
RN   [6]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9703985; DOI=10.1006/bbrc.1998.9034;
RA   Meyer-Wentrup F., Karbach U., Gorboulev V., Arndt P., Koepsell H.;
RT   "Membrane localization of the electrogenic cation transporter rOCT1 in rat
RT   liver.";
RL   Biochem. Biophys. Res. Commun. 248:673-678(1998).
RN   [7]
RP   TISSUE SPECIFICITY.
RC   TISSUE=Placenta;
RX   PubMed=9830022; DOI=10.1074/jbc.273.49.32776;
RA   Wu X., Kekuda R., Huang W., Fei Y.-J., Leibach F.H., Chen J., Conway S.J.,
RA   Ganapathy V.;
RT   "Identity of the organic cation transporter OCT3 as the extraneuronal
RT   monoamine transporter (uptake2) and evidence for the expression of the
RT   transporter in the brain.";
RL   J. Biol. Chem. 273:32776-32786(1998).
RN   [8]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND MISCELLANEOUS.
RX   PubMed=9776363; DOI=10.1038/sj.bjp.0702065;
RA   Breidert T., Spitzenberger F., Gruendemann D., Schoemig E.;
RT   "Catecholamine transport by the organic cation transporter type 1 (OCT1).";
RL   Br. J. Pharmacol. 125:218-224(1998).
RN   [9]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=9808712;
RA   Urakami Y., Okuda M., Masuda S., Saito H., Inui K.;
RT   "Functional characteristics and membrane localization of rat multispecific
RT   organic cation transporters, OCT1 and OCT2, mediating tubular secretion of
RT   cationic drugs.";
RL   J. Pharmacol. Exp. Ther. 287:800-805(1998).
RN   [10]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, SUBCELLULAR
RP   LOCATION, DOMAIN, MISCELLANEOUS, AND MUTAGENESIS OF ASP-475.
RX   PubMed=10570053; DOI=10.1124/mol.56.6.1254;
RA   Gorboulev V., Volk C., Arndt P., Akhoundova A., Koepsell H.;
RT   "Selectivity of the polyspecific cation transporter rOCT1 is changed by
RT   mutation of aspartate 475 to glutamate.";
RL   Mol. Pharmacol. 56:1254-1261(1999).
RN   [11]
RP   FUNCTION, SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=10997918; DOI=10.1152/ajprenal.2000.279.4.f679;
RA   Karbach U., Kricke J., Meyer-Wentrup F., Gorboulev V., Volk C.,
RA   Loffing-Cueni D., Kaissling B., Bachmann S., Koepsell H.;
RT   "Localization of organic cation transporters OCT1 and OCT2 in rat kidney.";
RL   Am. J. Physiol. 279:F679-F687(2000).
RN   [12]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=11083459; DOI=10.1007/s004180000186;
RA   Sugawara-Yokoo M., Urakami Y., Koyama H., Fujikura K., Masuda S., Saito H.,
RA   Naruse T., Inui K., Takata K.;
RT   "Differential localization of organic cation transporters rOCT1 and rOCT2
RT   in the basolateral membrane of rat kidney proximal tubules.";
RL   Histochem. Cell Biol. 114:175-180(2000).
RN   [13]
RP   FUNCTION, ACTIVITY REGULATION, AND PHOSPHORYLATION.
RX   PubMed=10864577; DOI=10.1681/asn.v1171216;
RA   Mehrens T., Lelleck S., Cetinkaya I., Knollmann M., Hohage H.,
RA   Gorboulev V., Boknik P., Koepsell H., Schlatter E.;
RT   "The affinity of the organic cation transporter rOCT1 is increased by
RT   protein kinase C-dependent phosphorylation.";
RL   J. Am. Soc. Nephrol. 11:1216-1224(2000).
RN   [14]
RP   FUNCTION, TRANSPORTER ACTIVITY, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11502595; DOI=10.1152/ajprenal.2001.281.3.f454;
RA   Arndt P., Volk C., Gorboulev V., Budiman T., Popp C., Ulzheimer-Teuber I.,
RA   Akhoundova A., Koppatz S., Bamberg E., Nagel G., Koepsell H.;
RT   "Interaction of cations, anions, and weak base quinine with rat renal
RT   cation transporter rOCT2 compared with rOCT1.";
RL   Am. J. Physiol. 281:F454-F468(2001).
RN   [15]
RP   FUNCTION, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=11408531;
RA   van Montfoort J.E., Mueller M., Groothuis G.M.M., Meijer D.K.F.,
RA   Koepsell H., Meier P.J.;
RT   "Comparison of 'type I' and 'type II' organic cation transport by organic
RT   cation transporters and organic anion-transporting polypeptides.";
RL   J. Pharmacol. Exp. Ther. 298:110-115(2001).
RN   [16]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=11758759; DOI=10.1023/a:1013070128668;
RA   Urakami Y., Okuda M., Masuda S., Akazawa M., Saito H., Inui K.;
RT   "Distinct characteristics of organic cation transporters, OCT1 and OCT2, in
RT   the basolateral membrane of renal tubules.";
RL   Pharm. Res. 18:1528-1534(2001).
RN   [17]
RP   TISSUE SPECIFICITY, AND DEVELOPMENTAL STAGE.
RX   PubMed=11792693; DOI=10.1124/dmd.30.2.212;
RA   Slitt A.L., Cherrington N.J., Hartley D.P., Leazer T.M., Klaassen C.D.;
RT   "Tissue distribution and renal developmental changes in rat organic cation
RT   transporter mRNA levels.";
RL   Drug Metab. Dispos. 30:212-219(2002).
RN   [18]
RP   FUNCTION, ACTIVITY REGULATION, AND MISCELLANEOUS.
RX   PubMed=12395288; DOI=10.1007/s00232-002-1023-7;
RA   Schlatter E., Moennich V., Cetinkaya I., Mehrens T., Ciarimboli G.,
RA   Hirsch J.R., Popp C., Koepsell H.;
RT   "The organic cation transporters rOCT1 and hOCT2 are inhibited by cGMP.";
RL   J. Membr. Biol. 189:237-244(2002).
RN   [19]
RP   INDUCTION.
RX   PubMed=15122767; DOI=10.1002/hep.20176;
RA   Denk G.U., Soroka C.J., Mennone A., Koepsell H., Beuers U., Boyer J.L.;
RT   "Down-regulation of the organic cation transporter 1 of rat liver in
RT   obstructive cholestasis.";
RL   Hepatology 39:1382-1389(2004).
RN   [20]
RP   FUNCTION, TRANSPORTER ACTIVITY, SUBCELLULAR LOCATION, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=15817714; DOI=10.1165/rcmb.2004-0363oc;
RA   Lips K.S., Volk C., Schmitt B.M., Pfeil U., Arndt P., Miska D., Ermert L.,
RA   Kummer W., Koepsell H.;
RT   "Polyspecific cation transporters mediate luminal release of acetylcholine
RT   from bronchial epithelium.";
RL   Am. J. Respir. Cell Mol. Biol. 33:79-88(2005).
RN   [21]
RP   FUNCTION, AND MISCELLANEOUS.
RX   PubMed=16142924; DOI=10.1021/bi050676c;
RA   Keller T., Elfeber M., Gorboulev V., Reilaender H., Koepsell H.;
RT   "Purification and functional reconstitution of the rat organic cation
RT   transporter OCT1.";
RL   Biochemistry 44:12253-12263(2005).
RN   [22]
RP   FUNCTION, AND MISCELLANEOUS.
RX   PubMed=15640376; DOI=10.1124/dmd.104.002519;
RA   Ishiguro N., Saito A., Yokoyama K., Morikawa M., Igarashi T., Tamai I.;
RT   "Transport of the dopamine D2 agonist pramipexole by rat organic cation
RT   transporters OCT1 and OCT2 in kidney.";
RL   Drug Metab. Dispos. 33:495-499(2005).
RN   [23]
RP   FUNCTION, TISSUE SPECIFICITY, AND MISCELLANEOUS.
RX   PubMed=16272756; DOI=10.2133/dmpk.20.379;
RA   Kimura N., Masuda S., Tanihara Y., Ueo H., Okuda M., Katsura T., Inui K.;
RT   "Metformin is a superior substrate for renal organic cation transporter
RT   OCT2 rather than hepatic OCT1.";
RL   Drug Metab. Pharmacokinet. 20:379-386(2005).
RN   [24]
RP   MUTAGENESIS OF SER-286; SER-292; THR-296; SER-328 AND THR-550, AND
RP   PHOSPHORYLATION.
RX   PubMed=15829703; DOI=10.1681/asn.2004040256;
RA   Ciarimboli G., Koepsell H., Iordanova M., Gorboulev V., Durner B., Lang D.,
RA   Edemir B., Schroter R., Van Le T., Schlatter E.;
RT   "Individual PKC-phosphorylation sites in organic cation transporter 1
RT   determine substrate selectivity and transport regulation.";
RL   J. Am. Soc. Nephrol. 16:1562-1570(2005).
RN   [25]
RP   FUNCTION, TRANSPORTER ACTIVITY, DOMAIN, MISCELLANEOUS, AND MUTAGENESIS OF
RP   MET-212; VAL-213; SER-214; LYS-215; GLY-216; SER-217; TRP-218; VAL-219;
RP   SER-220; GLY-221; TYR-222; THR-223; LEU-224; ILE-225; THR-226; GLU-227;
RP   PHE-228 AND VAL-229.
RX   PubMed=15662044; DOI=10.1124/mol.104.008839;
RA   Popp C., Gorboulev V., Mueller T.D., Gorbunov D., Shatskaya N.,
RA   Koepsell H.;
RT   "Amino acids critical for substrate affinity of rat organic cation
RT   transporter 1 line the substrate binding region in a model derived from the
RT   tertiary structure of lactose permease.";
RL   Mol. Pharmacol. 67:1600-1611(2005).
RN   [26]
RP   FUNCTION, TRANSPORTER ACTIVITY, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE
RP   SPECIFICITY, AND MISCELLANEOUS.
RX   PubMed=16581093; DOI=10.1016/j.neuropharm.2006.01.005;
RA   Amphoux A., Vialou V., Drescher E., Bruess M., Mannoury La Cour C.,
RA   Rochat C., Millan M.J., Giros B., Boenisch H., Gautron S.;
RT   "Differential pharmacological in vitro properties of organic cation
RT   transporters and regional distribution in rat brain.";
RL   Neuropharmacology 50:941-952(2006).
RN   [27]
RP   FUNCTION, TRANSPORTER ACTIVITY, DOMAIN, MISCELLANEOUS, AND MUTAGENESIS OF
RP   CYS-26; CYS-155; CYS-179; CYS-322; CYS-358; CYS-418; CYS-437; CYS-451;
RP   CYS-470 AND CYS-474.
RX   PubMed=17567940; DOI=10.1152/ajprenal.00106.2007;
RA   Sturm A., Gorboulev V., Gorbunov D., Keller T., Volk C., Schmitt B.M.,
RA   Schlachtbauer P., Ciarimboli G., Koepsell H.;
RT   "Identification of cysteines in rat organic cation transporters rOCT1
RT   (C322, C451) and rOCT2 (C451) critical for transport activity and substrate
RT   affinity.";
RL   Am. J. Physiol. 293:F767-F779(2007).
RN   [28]
RP   INDUCTION.
RX   PubMed=17553914; DOI=10.1124/dmd.107.015842;
RA   Maeda T., Oyabu M., Yotsumoto T., Higashi R., Nagata K., Yamazoe Y.,
RA   Tamai I.;
RT   "Effect of pregnane X receptor ligand on pharmacokinetics of substrates of
RT   organic cation transporter Oct1 in rats.";
RL   Drug Metab. Dispos. 35:1580-1586(2007).
RN   [29]
RP   FUNCTION, AND TISSUE SPECIFICITY.
RX   PubMed=17616214; DOI=10.1021/mp070023l;
RA   Maeda T., Goto A., Kobayashi D., Tamai I.;
RT   "Transport of organic cations across the blood-testis barrier.";
RL   Mol. Pharm. 4:600-607(2007).
RN   [30]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-334, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
CC   -!- FUNCTION: Electrogenic voltage-dependent transporter that mediates the
CC       transport of a variety of organic cations such as endogenous bioactive
CC       amines, cationic drugs and xenobiotics (PubMed:10570053,
CC       PubMed:10864577, PubMed:10997918, PubMed:11408531, PubMed:11502595,
CC       PubMed:12395288, PubMed:15640376, PubMed:15662044, PubMed:16142924,
CC       PubMed:16272756, PubMed:16581093, PubMed:17567940, PubMed:7990927,
CC       PubMed:8955087). Functions as a pH- and Na(+)-independent,
CC       bidirectional transporter (PubMed:16142924, PubMed:8955087). Cation
CC       cellular uptake or release is driven by the electrochemical potential
CC       (i.e. membrane potential and concentration gradient) and substrate
CC       selectivity (PubMed:16142924, PubMed:17567940, PubMed:8955087,
CC       PubMed:9405386). Hydrophobicity is a major requirement for recognition
CC       in polyvalent substrates and inhibitors (By similarity). Primarily
CC       expressed in the basolateral membrane of hepatocytes and proximal
CC       tubules and involved in the uptake and disposition of cationic
CC       compounds from the blood by hepatic and renal clearance
CC       (PubMed:10997918, PubMed:7990927, PubMed:9703985). Most likely
CC       functions as an uptake carrier in enterocytes contributing to the
CC       intestinal excretion and elimination of organic cations from the
CC       systemic circulation (By similarity). Transports endogenous monoamines
CC       such as N-1-methylnicotinamide (NMN), guanidine, neurotransmitters
CC       dopamine, serotonin, noradrenaline, adrenaline and histamine, and
CC       quaternary ammonium compound such as choline (PubMed:10570053,
CC       PubMed:11408531, PubMed:11502595, PubMed:11758759, PubMed:15662044,
CC       PubMed:16581093, PubMed:17567940, PubMed:8955087, PubMed:9776363). Also
CC       transports natural polyamines such as spermidine, agmatine and
CC       putrescine at low affinity, but relatively high turnover (By
CC       similarity). Involved in the hepatic uptake of vitamin B1/thiamine,
CC       hence regulating hepatic lipid and energy metabolism (By similarity).
CC       Contributes to the influx and efflux of fatty acid carriers carnitines
CC       and acylcarnitines across the basolateral membrane of hepatocytes, from
CC       the liver to the systemic circulation and inversely and may be involved
CC       in regulating the systemic availability of hepatic acylcarnitines (By
CC       similarity). Mediates the bidirectional transport of acetylcholine
CC       (ACh) at the apical membrane of ciliated cell in airway epithelium,
CC       thereby playing a role in luminal release of ACh from bronchial
CC       epithelium (PubMed:15817714). Transports dopaminergic neuromodulators
CC       cyclo(his-pro) and salsolinol with lower efficency (By similarity).
CC       Also capable of transporting non-amine endogenous compounds such as
CC       prostaglandin E2 (PGE2) and prostaglandin F2-alpha (PGF2-alpha) (By
CC       similarity). May contribute to the transport of cationic compounds in
CC       testis across the blood-testis-barrier (Probable). Also mediates the
CC       uptake of xenobiotics tributylmethylammonium (TBuMA), quinidine, N-
CC       methyl-quinine (NMQ), N-methyl-quinidine (NMQD) N-(4,4-azo-n-pentyl)-
CC       quinuclidine (APQ), azidoprocainamide methoiodide (AMP), N-(4,4-azo-n-
CC       pentyl)-21-deoxyajmalinium (APDA) and 4-(4-(dimethylamino)styryl)-N-
CC       methylpyridinium (ASP) (PubMed:10864577, PubMed:11408531,
CC       PubMed:12395288, PubMed:8955087). {ECO:0000250|UniProtKB:O08966,
CC       ECO:0000250|UniProtKB:O15245, ECO:0000269|PubMed:10570053,
CC       ECO:0000269|PubMed:10864577, ECO:0000269|PubMed:10997918,
CC       ECO:0000269|PubMed:11408531, ECO:0000269|PubMed:11502595,
CC       ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:12395288,
CC       ECO:0000269|PubMed:15640376, ECO:0000269|PubMed:15662044,
CC       ECO:0000269|PubMed:15817714, ECO:0000269|PubMed:16142924,
CC       ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16581093,
CC       ECO:0000269|PubMed:17567940, ECO:0000269|PubMed:7990927,
CC       ECO:0000269|PubMed:8955087, ECO:0000269|PubMed:9405386,
CC       ECO:0000269|PubMed:9703985, ECO:0000269|PubMed:9776363,
CC       ECO:0000305|PubMed:17616214}.
CC   -!- FUNCTION: [Isoform 2]: Functional isoform capable of transporting TEA.
CC       {ECO:0000269|PubMed:9195965}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-methylnicotinamide(out) = 1-methylnicotinamide(in);
CC         Xref=Rhea:RHEA:73859, ChEBI:CHEBI:16797;
CC         Evidence={ECO:0000269|PubMed:10570053, ECO:0000269|PubMed:11502595,
CC         ECO:0000269|PubMed:8955087};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dopamine(out) = dopamine(in); Xref=Rhea:RHEA:73863,
CC         ChEBI:CHEBI:59905; Evidence={ECO:0000269|PubMed:16581093,
CC         ECO:0000269|PubMed:9776363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=serotonin(out) = serotonin(in); Xref=Rhea:RHEA:73867,
CC         ChEBI:CHEBI:350546; Evidence={ECO:0000269|PubMed:15662044,
CC         ECO:0000269|PubMed:16581093, ECO:0000269|PubMed:9776363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-adrenaline(out) = (R)-adrenaline(in);
CC         Xref=Rhea:RHEA:73875, ChEBI:CHEBI:71406;
CC         Evidence={ECO:0000269|PubMed:16581093};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-noradrenaline(out) = (R)-noradrenaline(in);
CC         Xref=Rhea:RHEA:73871, ChEBI:CHEBI:72587;
CC         Evidence={ECO:0000269|PubMed:16581093, ECO:0000269|PubMed:9776363};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=histamine(out) = histamine(in); Xref=Rhea:RHEA:73879,
CC         ChEBI:CHEBI:58432; Evidence={ECO:0000269|PubMed:11502595,
CC         ECO:0000269|PubMed:15662044};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=guanidine(out) = guanidine(in); Xref=Rhea:RHEA:73883,
CC         ChEBI:CHEBI:30087; Evidence={ECO:0000269|PubMed:11502595,
CC         ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:15662044};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=choline(out) = choline(in); Xref=Rhea:RHEA:32751,
CC         ChEBI:CHEBI:15354; Evidence={ECO:0000269|PubMed:10570053,
CC         ECO:0000269|PubMed:11502595, ECO:0000269|PubMed:17567940,
CC         ECO:0000269|PubMed:8955087};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=acetylcholine(in) = acetylcholine(out); Xref=Rhea:RHEA:74663,
CC         ChEBI:CHEBI:15355; Evidence={ECO:0000269|PubMed:15817714};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=thiamine(in) = thiamine(out); Xref=Rhea:RHEA:34919,
CC         ChEBI:CHEBI:18385; Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=agmatine(out) = agmatine(in); Xref=Rhea:RHEA:72131,
CC         ChEBI:CHEBI:58145; Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=putrescine(out) = putrescine(in); Xref=Rhea:RHEA:72135,
CC         ChEBI:CHEBI:326268; Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=spermidine(in) = spermidine(out); Xref=Rhea:RHEA:35039,
CC         ChEBI:CHEBI:57834; Evidence={ECO:0000305|PubMed:8955087};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-carnitine(in) = (R)-carnitine(out); Xref=Rhea:RHEA:34959,
CC         ChEBI:CHEBI:16347; Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-isobutanoyl-(R)-carnitine(in) = O-isobutanoyl-(R)-
CC         carnitine(out); Xref=Rhea:RHEA:74315, ChEBI:CHEBI:84838;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-acetyl-(R)-carnitine(in) = O-acetyl-(R)-carnitine(out);
CC         Xref=Rhea:RHEA:74319, ChEBI:CHEBI:57589;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-3-hydroxybutanoyl-(R)-carnitine(in) = O-3-hydroxybutanoyl-
CC         (R)-carnitine(out); Xref=Rhea:RHEA:74323, ChEBI:CHEBI:84842;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-propanoyl-(R)-carnitine(in) = O-propanoyl-(R)-
CC         carnitine(out); Xref=Rhea:RHEA:74327, ChEBI:CHEBI:53210;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-butanoyl-(R)-carnitine(in) = O-butanoyl-(R)-carnitine(out);
CC         Xref=Rhea:RHEA:74331, ChEBI:CHEBI:21949;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-2-methylbutanoyl-(R)-carnitine(in) = O-2-methylbutanoyl-(R)-
CC         carnitine(out); Xref=Rhea:RHEA:74335, ChEBI:CHEBI:84840;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-3-methylbutanoyl-(R)-carnitine(in) = O-3-methylbutanoyl-(R)-
CC         carnitine(out); Xref=Rhea:RHEA:74339, ChEBI:CHEBI:70819;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O-hexanoyl-(R)-carnitine(in) = O-hexanoyl-(R)-carnitine(out);
CC         Xref=Rhea:RHEA:74343, ChEBI:CHEBI:84834;
CC         Evidence={ECO:0000250|UniProtKB:O08966};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=L-histidyl-L-proline diketopiperazine(in) = L-histidyl-L-
CC         proline diketopiperazine(out); Xref=Rhea:RHEA:74787,
CC         ChEBI:CHEBI:90039; Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(R)-salsolinol(in) = (R)-salsolinol(out);
CC         Xref=Rhea:RHEA:74791, ChEBI:CHEBI:194082;
CC         Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin F2alpha(out) = prostaglandin F2alpha(in);
CC         Xref=Rhea:RHEA:50988, ChEBI:CHEBI:57404;
CC         Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=prostaglandin E2(out) = prostaglandin E2(in);
CC         Xref=Rhea:RHEA:50984, ChEBI:CHEBI:606564;
CC         Evidence={ECO:0000250|UniProtKB:O15245};
CC   -!- ACTIVITY REGULATION: Phosphorylation of the transporter leads to
CC       changes in its substrate affinity, resulting in a regulation of the
CC       transport activity (PubMed:10864577). In contrast with human ortholog,
CC       ASP uptake is stimulated by protein kinase A (PKA) and C (PKC) and
CC       endogenous tyrosine kinase activation (PubMed:10864577). ASP affinity
CC       is induced by PKC-dependent phosphorylation (PubMed:10864577).
CC       Inhibited by cGMP, most likely through a cGMP-binding protein that
CC       interacts with OCT1 (PubMed:12395288). {ECO:0000269|PubMed:10864577,
CC       ECO:0000269|PubMed:12395288}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=300 uM for histamine {ECO:0000269|PubMed:11502595};
CC         KM=340 uM for NMN {ECO:0000269|PubMed:8955087};
CC         KM=126 uM for NMN {ECO:0000269|PubMed:10570053};
CC         KM=800 uM for noradrenaline {ECO:0000269|PubMed:16581093};
CC         KM=900 uM for serotonin {ECO:0000269|PubMed:16581093};
CC         KM=1100 uM for adrenaline {ECO:0000269|PubMed:16581093};
CC         KM=1100 uM for choline {ECO:0000269|PubMed:8955087};
CC         KM=370 uM for choline {ECO:0000269|PubMed:10570053};
CC         KM=1600 uM for dopamine {ECO:0000269|PubMed:16581093};
CC         KM=1660 uM for guanidine {ECO:0000269|PubMed:11502595};
CC         KM=17.3 uM for NMQ {ECO:0000269|PubMed:11408531};
CC         KM=7.4 uM for NMQD {ECO:0000269|PubMed:11408531};
CC         KM=34 uM for TBuMA {ECO:0000269|PubMed:11408531};
CC         KM=54 uM for APM {ECO:0000269|PubMed:11408531};
CC       pH dependence:
CC         Optimum pH is 6.0 for the transport of the drug quinidine. No
CC         transport activity is observed at pH 7.5, possibly due to the
CC         protonation of quininide at pH6.0 (PubMed:11408531). TEA transport is
CC         independent of any pH (PubMed:8955087). {ECO:0000269|PubMed:11408531,
CC         ECO:0000269|PubMed:8955087};
CC   -!- INTERACTION:
CC       Q63089; Q63089: Slc22a1; NbExp=4; IntAct=EBI-5261153, EBI-5261153;
CC   -!- SUBCELLULAR LOCATION: Basolateral cell membrane
CC       {ECO:0000269|PubMed:10997918, ECO:0000269|PubMed:11083459,
CC       ECO:0000269|PubMed:7990927, ECO:0000269|PubMed:9703985,
CC       ECO:0000269|PubMed:9808712}; Multi-pass membrane protein {ECO:0000305}.
CC       Apical cell membrane {ECO:0000269|PubMed:15817714}; Multi-pass membrane
CC       protein {ECO:0000305}. Lateral cell membrane
CC       {ECO:0000250|UniProtKB:O15245}; Multi-pass membrane protein
CC       {ECO:0000305}. Basal cell membrane {ECO:0000250|UniProtKB:O15245};
CC       Multi-pass membrane protein {ECO:0000305}. Cell membrane
CC       {ECO:0000269|PubMed:10570053}; Multi-pass membrane protein
CC       {ECO:0000305}. Note=Localized to the sinusoidal/basolateral membrane of
CC       hepatocytes (PubMed:9703985). Mainly localized to the basolateral
CC       membrane of renal proximal tubular cells (PubMed:10997918,
CC       PubMed:11083459, PubMed:7990927, PubMed:9808712). Localized to the
CC       luminal/apical membrane of ciliated epithelial cells in the airway
CC       (PubMed:15817714). {ECO:0000250|UniProtKB:O15245,
CC       ECO:0000269|PubMed:10997918, ECO:0000269|PubMed:11083459,
CC       ECO:0000269|PubMed:15817714, ECO:0000269|PubMed:7990927,
CC       ECO:0000269|PubMed:9703985, ECO:0000269|PubMed:9808712}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q63089-1; Sequence=Displayed;
CC       Name=2; Synonyms=rOCT1A, Pro 2;
CC         IsoId=Q63089-2; Sequence=VSP_033591, VSP_033592;
CC   -!- TISSUE SPECIFICITY: Expressed in kidney cortex in S1, S2 segments of
CC       renal proximal tubules as well as in kidney medulla (PubMed:10997918,
CC       PubMed:11083459, PubMed:11758759, PubMed:11792693, PubMed:16272756,
CC       PubMed:7990927, PubMed:9195965, PubMed:9808712, PubMed:9830022).
CC       Expressed throughout the liver lobuli, in hepatocytes surrounding the
CC       central veins (PubMed:16272756, PubMed:7990927, PubMed:9195965,
CC       PubMed:9703985, PubMed:9830022). Expressed in enterocytes of villi and
CC       crypts in small intestine (PubMed:7990927, PubMed:9195965,
CC       PubMed:9830022). Expressed in brain, in some white matter regions like
CC       the corpus callosum and in the granular layer of the cerebellum
CC       (PubMed:11792693, PubMed:16581093). Expressed in Sertoli cells in
CC       testis (PubMed:17616214). Expressed in colon (PubMed:7990927,
CC       PubMed:9195965). Expressed in tracheal and bronchial ciliated
CC       epithelium in the respiratory tract (PubMed:15817714). Expressed in
CC       spleen, moderately in skin, and weakly in the gastrointestinal tract,
CC       lung, thymus, muscle, and prostate (PubMed:11792693).
CC       {ECO:0000269|PubMed:10997918, ECO:0000269|PubMed:11083459,
CC       ECO:0000269|PubMed:11758759, ECO:0000269|PubMed:11792693,
CC       ECO:0000269|PubMed:15817714, ECO:0000269|PubMed:16272756,
CC       ECO:0000269|PubMed:16581093, ECO:0000269|PubMed:17616214,
CC       ECO:0000269|PubMed:7990927, ECO:0000269|PubMed:9195965,
CC       ECO:0000269|PubMed:9703985, ECO:0000269|PubMed:9808712}.
CC   -!- TISSUE SPECIFICITY: [Isoform 2]: Expressed in kidney cortex and medulla
CC       (PubMed:9195965). Expressed in intestine, liver and colon
CC       (PubMed:9195965). {ECO:0000269|PubMed:9195965}.
CC   -!- DEVELOPMENTAL STAGE: Renal level increases gradually from postnatal day
CC       1 through day 45 in both genders. {ECO:0000269|PubMed:11792693}.
CC   -!- INDUCTION: Down-regulated in obstructive cholestasis. Up-regulated by
CC       treatment with pregnenolone-16 alpha-carbonitrile (PCN) and by
CC       overexpression of pregnane X receptor (PXR).
CC       {ECO:0000269|PubMed:15122767, ECO:0000269|PubMed:17553914}.
CC   -!- DOMAIN: A large substrate binding region with partially overlapping
CC       binding domains for structurally different substrates is formed by
CC       several transmembrane helix domains (TMH) including TMH 2, 4, 10 and
CC       11, and it is alternatingly exposed to the extracellular or
CC       intracellular side during substrate transport.
CC       {ECO:0000305|PubMed:10570053, ECO:0000305|PubMed:15662044,
CC       ECO:0000305|PubMed:17567940}.
CC   -!- DOMAIN: Contains one proline-rich sequence (Pro-Glu-Ser-Pro-Arg) that
CC       is required for transport activity. {ECO:0000250|UniProtKB:O15245}.
CC   -!- PTM: Phosphorylated. {ECO:0000269|PubMed:10864577,
CC       ECO:0000269|PubMed:15829703}.
CC   -!- MISCELLANEOUS: Involved in the uptake of clinically used drugs
CC       including diabete treatment medicine metformin, neurotoxins 1-methyl-4-
CC       phenylpyridinium (MPP(+)) and iobenguane and platinum-based drug
CC       cisplatin (PubMed:10570053, PubMed:12395288, PubMed:15640376,
CC       PubMed:15662044, PubMed:16142924, PubMed:16272756, PubMed:16581093,
CC       PubMed:17567940, PubMed:8955087, PubMed:9776363). Metformin
CC       competitively inhibits OCT1-mediated thiamine uptake, leading to a
CC       decrease in hepatic steatosis (By similarity). Plays a role in the
CC       anticancer activity of cisplatin and may contribute to antitumor
CC       specificity (By similarity). {ECO:0000250|UniProtKB:O08966,
CC       ECO:0000250|UniProtKB:O15245, ECO:0000269|PubMed:10570053,
CC       ECO:0000269|PubMed:12395288, ECO:0000269|PubMed:15640376,
CC       ECO:0000269|PubMed:15662044, ECO:0000269|PubMed:16142924,
CC       ECO:0000269|PubMed:16272756, ECO:0000269|PubMed:16581093,
CC       ECO:0000269|PubMed:17567940, ECO:0000269|PubMed:8955087,
CC       ECO:0000269|PubMed:9776363}.
CC   -!- SIMILARITY: Belongs to the major facilitator (TC 2.A.1) superfamily.
CC       Organic cation transporter (TC 2.A.1.19) family. {ECO:0000305}.
CC   -!- CAUTION: Cellular localization of OCT1 in the intestine and the kidney
CC       remains to be finally defined. While most authors have deduced a
CC       localization at the basolateral side of enterocytes consistent with a
CC       physiological role in organic anions uptake from the blood flow and
CC       intestinal excretion (By similarity), other studies demonstrated an
CC       apical localization (By similarity), supporting a function in
CC       intestinal absorption of organic anions and drugs (By similarity).
CC       Similarly, contradictory findings have shown a localization to the
CC       basolateral side (PubMed:7990927, PubMed:9808712, PubMed:10997918,
CC       PubMed:11083459) or to the apical side (By similarity) of proximal
CC       tubules (By similarity) (PubMed:10997918, PubMed:11083459,
CC       PubMed:7990927, PubMed:9808712). Affinity and capacity of the
CC       transporter for endogenous substrates vary among orthologs (By
CC       similarity). {ECO:0000250|UniProtKB:O15245,
CC       ECO:0000269|PubMed:10997918, ECO:0000269|PubMed:11083459,
CC       ECO:0000269|PubMed:7990927, ECO:0000269|PubMed:9808712}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAH78883.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X78855; CAA55411.1; -; mRNA.
DR   EMBL; U76379; AAB67702.1; -; mRNA.
DR   EMBL; BC078883; AAH78883.1; ALT_INIT; mRNA.
DR   PIR; S50862; S50862.
DR   RefSeq; NP_036829.1; NM_012697.1. [Q63089-1]
DR   AlphaFoldDB; Q63089; -.
DR   SMR; Q63089; -.
DR   IntAct; Q63089; 1.
DR   STRING; 10116.ENSRNOP00000022254; -.
DR   BindingDB; Q63089; -.
DR   ChEMBL; CHEMBL2073670; -.
DR   TCDB; 2.A.1.19.1; the major facilitator superfamily (mfs).
DR   GlyCosmos; Q63089; 1 site, No reported glycans.
DR   GlyGen; Q63089; 1 site.
DR   iPTMnet; Q63089; -.
DR   PhosphoSitePlus; Q63089; -.
DR   PaxDb; 10116-ENSRNOP00000022254; -.
DR   Ensembl; ENSRNOT00000022068.6; ENSRNOP00000022068.3; ENSRNOG00000016337.8. [Q63089-2]
DR   Ensembl; ENSRNOT00000022254.6; ENSRNOP00000022254.2; ENSRNOG00000016337.8. [Q63089-1]
DR   Ensembl; ENSRNOT00055048073; ENSRNOP00055039572; ENSRNOG00055027731. [Q63089-1]
DR   Ensembl; ENSRNOT00060016640; ENSRNOP00060013002; ENSRNOG00060009846. [Q63089-1]
DR   Ensembl; ENSRNOT00065050514; ENSRNOP00065041511; ENSRNOG00065029234. [Q63089-1]
DR   GeneID; 24904; -.
DR   KEGG; rno:24904; -.
DR   AGR; RGD:3224; -.
DR   CTD; 6580; -.
DR   RGD; 3224; Slc22a1.
DR   eggNOG; KOG0255; Eukaryota.
DR   GeneTree; ENSGT00940000162065; -.
DR   HOGENOM; CLU_001265_33_5_1; -.
DR   InParanoid; Q63089; -.
DR   OMA; IMIFIPH; -.
DR   OrthoDB; 1474205at2759; -.
DR   PhylomeDB; Q63089; -.
DR   Reactome; R-RNO-112311; Neurotransmitter clearance.
DR   Reactome; R-RNO-181430; Norepinephrine Neurotransmitter Release Cycle.
DR   Reactome; R-RNO-2161517; Abacavir transmembrane transport.
DR   Reactome; R-RNO-442660; Na+/Cl- dependent neurotransmitter transporters.
DR   Reactome; R-RNO-549127; Organic cation transport.
DR   Reactome; R-RNO-9793528; Ciprofloxacin ADME.
DR   SABIO-RK; Q63089; -.
DR   PRO; PR:Q63089; -.
DR   Proteomes; UP000002494; Chromosome 1.
DR   Bgee; ENSRNOG00000016337; Expressed in adult mammalian kidney and 13 other cell types or tissues.
DR   GO; GO:0016324; C:apical plasma membrane; IDA:UniProtKB.
DR   GO; GO:0009925; C:basal plasma membrane; ISO:RGD.
DR   GO; GO:0016323; C:basolateral plasma membrane; IDA:UniProtKB.
DR   GO; GO:0016328; C:lateral plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IDA:MGI.
DR   GO; GO:0098793; C:presynapse; IEA:GOC.
DR   GO; GO:1901235; F:(R)-carnitine transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0005277; F:acetylcholine transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005330; F:dopamine:sodium symporter activity; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0008504; F:monoamine transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005326; F:neurotransmitter transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0005334; F:norepinephrine:sodium symporter activity; IDA:RGD.
DR   GO; GO:0008514; F:organic anion transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015101; F:organic cation transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0015132; F:prostaglandin transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015489; F:putrescine transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015214; F:pyrimidine nucleoside transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0015651; F:quaternary ammonium group transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:0008513; F:secondary active organic cation transmembrane transporter activity; IDA:RGD.
DR   GO; GO:0015606; F:spermidine transmembrane transporter activity; ISS:UniProtKB.
DR   GO; GO:0015234; F:thiamine transmembrane transporter activity; ISO:RGD.
DR   GO; GO:0019534; F:toxin transmembrane transporter activity; IMP:ARUK-UCL.
DR   GO; GO:0042910; F:xenobiotic transmembrane transporter activity; IDA:UniProtKB.
DR   GO; GO:1902270; P:(R)-carnitine transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0015870; P:acetylcholine transport; IDA:UniProtKB.
DR   GO; GO:1902616; P:acyl carnitine transmembrane transport; ISS:UniProtKB.
DR   GO; GO:1990748; P:cellular detoxification; IMP:ARUK-UCL.
DR   GO; GO:0015872; P:dopamine transport; IDA:UniProtKB.
DR   GO; GO:0090494; P:dopamine uptake; ISO:RGD.
DR   GO; GO:0048241; P:epinephrine transport; IDA:UniProtKB.
DR   GO; GO:0010248; P:establishment or maintenance of transmembrane electrochemical gradient; IDA:RGD.
DR   GO; GO:0072237; P:metanephric proximal tubule development; IEP:RGD.
DR   GO; GO:0015844; P:monoamine transport; IDA:UniProtKB.
DR   GO; GO:0098655; P:monoatomic cation transmembrane transport; IDA:RGD.
DR   GO; GO:0006812; P:monoatomic cation transport; ISO:RGD.
DR   GO; GO:0006836; P:neurotransmitter transport; ISO:RGD.
DR   GO; GO:0015874; P:norepinephrine transport; IDA:UniProtKB.
DR   GO; GO:0015695; P:organic cation transport; IDA:RGD.
DR   GO; GO:0015732; P:prostaglandin transport; ISS:UniProtKB.
DR   GO; GO:0015847; P:putrescine transport; ISS:UniProtKB.
DR   GO; GO:0015697; P:quaternary ammonium group transport; IDA:RGD.
DR   GO; GO:0006837; P:serotonin transport; IDA:UniProtKB.
DR   GO; GO:0051610; P:serotonin uptake; ISO:RGD.
DR   GO; GO:0015848; P:spermidine transport; ISS:UniProtKB.
DR   GO; GO:0071934; P:thiamine transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0015888; P:thiamine transport; ISS:UniProtKB.
DR   GO; GO:0042908; P:xenobiotic transport; IDA:UniProtKB.
DR   GO; GO:1990962; P:xenobiotic transport across blood-brain barrier; NAS:ARUK-UCL.
DR   Gene3D; 1.20.1250.20; MFS general substrate transporter like domains; 1.
DR   InterPro; IPR020846; MFS_dom.
DR   InterPro; IPR005828; MFS_sugar_transport-like.
DR   InterPro; IPR036259; MFS_trans_sf.
DR   InterPro; IPR004749; Orgcat_transp/SVOP.
DR   InterPro; IPR005829; Sugar_transporter_CS.
DR   NCBIfam; TIGR00898; 2A0119; 1.
DR   PANTHER; PTHR24064; SOLUTE CARRIER FAMILY 22 MEMBER; 1.
DR   PANTHER; PTHR24064:SF291; SOLUTE CARRIER FAMILY 22 MEMBER 1; 1.
DR   Pfam; PF00083; Sugar_tr; 1.
DR   SUPFAM; SSF103473; MFS general substrate transporter; 1.
DR   PROSITE; PS50850; MFS; 1.
DR   PROSITE; PS00216; SUGAR_TRANSPORT_1; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Glycoprotein; Ion transport; Membrane;
KW   Phosphoprotein; Reference proteome; Transmembrane; Transmembrane helix;
KW   Transport.
FT   CHAIN           1..556
FT                   /note="Solute carrier family 22 member 1"
FT                   /id="PRO_0000333879"
FT   TOPO_DOM        1..21
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        22..42
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        43..150
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        151..171
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        172..177
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        178..198
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        199..211
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        212..231
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        232..238
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        239..259
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        260..263
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        264..284
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        285..348
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        349..369
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        370..377
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        378..398
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        399..403
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        404..424
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        425..429
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        430..452
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        453..465
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        466..486
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        487..493
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        494..514
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        515..556
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOTIF           284..288
FT                   /note="Proline-rich sequence"
FT                   /evidence="ECO:0000250|UniProtKB:O15245"
FT   MOD_RES         334
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         543
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O15245"
FT   CARBOHYD        71
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   VAR_SEQ         1..126
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9195965"
FT                   /id="VSP_033591"
FT   VAR_SEQ         127..172
FT                   /note="VYDTPGSSIVTEFNLVCGDAWKVDLFQSCVNLGFFLGSLVVGYIAD -> MR
FT                   WTGTRAPLTVWTHCPAWLPTGVSCHWAPASMAGYTTLPAPPSSL (in isoform
FT                   2)"
FT                   /evidence="ECO:0000303|PubMed:15489334,
FT                   ECO:0000303|PubMed:9195965"
FT                   /id="VSP_033592"
FT   MUTAGEN         26
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-155; A-179; S-322; A-358; A-
FT                   418; S-437; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         155
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-179; S-322; A-358; A-
FT                   418; S-437; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         179
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; S-322; A-358; A-
FT                   418; S-437; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         212
FT                   /note="M->L: No change in TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         213
FT                   /note="V->G: Decreased TEA uptake. No change in MPP(+)
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         214
FT                   /note="S->G: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         215
FT                   /note="K->Q: Loss of TEA and MPP(+) uptake activity."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         215
FT                   /note="K->R: Loss of TEA and MPP(+) uptake activity."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         216
FT                   /note="G->A: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         217
FT                   /note="S->G: No change in TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         218
FT                   /note="W->F: Decreased guanidine, histamine, serotonin and
FT                   TEA uptake. No change in MPP(+) uptake. No change in TEA
FT                   and MPP(+) affinity. Decreased TEA Vmax. No change in
FT                   MPP(+) Vmax."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         218
FT                   /note="W->L: Decreased guanidine, histamine, serotonin, TEA
FT                   and MPP(+) uptake. Decreased TEA affinity. No change in
FT                   MPP(+) affinity. Decreased TEA and MPP(+) Vmax."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         218
FT                   /note="W->Y: Decreased guanidine, histamine, serotonin and
FT                   TEA uptake. No change in MPP(+) uptake. Increased TEA and
FT                   MPP(+) affinity. Decreased TEA and MPP(+) Vmax."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         219
FT                   /note="V->L: No change in TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         220
FT                   /note="S->I: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         221
FT                   /note="G->A: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         222
FT                   /note="Y->F: No change in guanidine, histamine, serotonin,
FT                   TEA and MPP(+) uptake. Increased TEA affinity. No change in
FT                   MPP(+) affinity. Decreased TEA Vmax. No change in MPP(+)
FT                   Vmax."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         222
FT                   /note="Y->L: Decreased guanidine, serotonin, TEA and MPP(+)
FT                   uptake. No change in histamine uptake. Increased TEA and
FT                   MPP(+) affinity. Decreased TEA and MPP(+) Vmax."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         223
FT                   /note="T->I: Decreased TEA uptake. No change in MPP(+)
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         224
FT                   /note="L->V: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         225
FT                   /note="I->G: No change in TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         226
FT                   /note="T->A: Decreased TEA uptake. No change in MPP(+)
FT                   uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         227
FT                   /note="E->D: Loss of TEA and MPP(+) uptake activity."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         227
FT                   /note="E->Q: Loss of TEA and MPP(+) uptake activity."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         228
FT                   /note="F->I: No change in TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         229
FT                   /note="V->A: Decreased TEA and MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         229
FT                   /note="V->L: Loss of TEA and MPP(+) uptake activity."
FT                   /evidence="ECO:0000269|PubMed:15662044"
FT   MUTAGEN         286
FT                   /note="S->A: No effect of PKC-induced stimulation on ASP
FT                   uptake. No effect of PKC-induced stimulation on ASP uptake;
FT                   when associated with A-292; A-296; A-328 and A-550. No
FT                   effect of PKA activation on ASP uptake. No effect of PKA
FT                   activation on ASP uptake; when associated with A-292; A-
FT                   296; A-328 and A-550. Significant reduction of ASP uptake
FT                   by p56(lck) tyrosine kinase-induced inhibition. Significant
FT                   reduction of ASP uptake by p56(lck) tyrosine kinase-induced
FT                   inhibition; when associated with A-292; A-296; A-328 and A-
FT                   550. No significant effect on trafficking from
FT                   intracellular pools to the cell membrane; when associated
FT                   with A-292; A-296; A-328 and A-550. suppresses
FT                   phosphorylation by PKC; when associated with A-292; A-296;
FT                   A-328 and A-550."
FT                   /evidence="ECO:0000269|PubMed:15829703"
FT   MUTAGEN         292
FT                   /note="S->A: No effect of PKC-induced stimulation on ASP
FT                   uptake. No effect of PKC-induced stimulation on ASP uptake;
FT                   when associated with A-286; A-296; A-328 and A-550. No
FT                   effect of PKA activation on ASP uptake. No effect of PKA
FT                   activation on ASP uptake; when associated with A-286; A-
FT                   296; A-328 and A-550. Significant reduction of ASP uptake
FT                   by p56(lck) tyrosine kinase-induced inhibition. Significant
FT                   reduction of ASP uptake by p56(lck) tyrosine kinase-induced
FT                   inhibition; when associated with A-286; A-296; A-328 and A-
FT                   550. No significant effect on trafficking from
FT                   intracellular pools to the cell membrane; when associated
FT                   with A-286; A-296; A-328 and A-550. suppresses
FT                   phosphorylation by PKC; when associated with A-286; A-296;
FT                   A-328 and A-550."
FT                   /evidence="ECO:0000269|PubMed:15829703"
FT   MUTAGEN         296
FT                   /note="T->A: No effect of PKC-induced stimulation on ASP
FT                   uptake. No effect of PKC-induced stimulation on ASP uptake;
FT                   when associated with A-286; A-292; A-328; A-550.
FT                   Significant increase of the ASP uptake by PKA activation.
FT                   No effect of PKA activation on ASP uptake; when associated
FT                   with A-286; A-292; A-328; A-550. Significant reduction of
FT                   ASP uptake by p56(lck) tyrosine kinase-induced inhibition.
FT                   Significant reduction of ASP uptake by p56(lck) tyrosine
FT                   kinase-induced inhibition; when associated with A-286; A-
FT                   292; A-328; A-550. No significant effect on trafficking
FT                   from intracellular pools to the cell membrane; when
FT                   associated with A-286; A-292; A-328 and A-550. suppresses
FT                   phosphorylation by PKC; when associated with A-286; A-292;
FT                   A-328 and A-550."
FT                   /evidence="ECO:0000269|PubMed:15829703"
FT   MUTAGEN         322
FT                   /note="C->S: Reduces the activation by MMTS. Abolishes the
FT                   activation by MMTs; when associated with M-451. Choline
FT                   affinity is increased fivefold by MMTS. Choline affinity is
FT                   increased fourfold by MMTS; when associated with A-26; A-
FT                   155; A-179; A-358; A-418; S-437; A-470 and A-474. Choline
FT                   affinity is increased four- to fivefold; when associated
FT                   with M-451."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         328
FT                   /note="S->A: No effect of PKC-induced stimulation on ASP
FT                   uptake. No effect of PKC-induced stimulation on ASP uptake;
FT                   when associated with A-286; A-292; A-296 and A-550. No
FT                   effect of PKA activation on ASP uptake. No effect of PKA
FT                   activation on ASP uptake; when associated with A-286; A-
FT                   292; A-296 and A-550. Significant reduction of ASP uptake
FT                   by p56(lck) tyrosine kinase-induced inhibition. Significant
FT                   reduction of ASP uptake by p56(lck) tyrosine kinase-induced
FT                   inhibition; when associated with A-286; A-292; A-296; A-
FT                   550. No significant effect on trafficking from
FT                   intracellular pools to the cell membrane; when associated
FT                   with A-286; A-292; A-296 and A-550. suppresses
FT                   phosphorylation by PKC; when associated with A-286; A-292;
FT                   A-296 and A-550."
FT                   /evidence="ECO:0000269|PubMed:15829703"
FT   MUTAGEN         358
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; A-179; S-322; A-
FT                   418; S-437; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         418
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; A-179; S-322; A-
FT                   358; S-437; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         437
FT                   /note="C->S: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; A-179; S-322; A-
FT                   358; A-418; A-470 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         451
FT                   /note="C->M: Reduces the activation by MMTS. Abolishes the
FT                   activation by MMTs; when associated with S-322. Abolishes
FT                   the effect of MMTs on choline-induced currents. Choline
FT                   affinity is not influenced by MMTS. Choline affinity is
FT                   increased four- to fivefold; when associated with S-322."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         470
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; A-179; S-322; A-
FT                   358; A-418; A-437 and A-474."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         474
FT                   /note="C->A: Choline affinity is increased fourfold by
FT                   MMTS; when associated with A-26; A-155; A-179; S-322; A-
FT                   358; A-418; A-437 and A-470."
FT                   /evidence="ECO:0000269|PubMed:17567940"
FT   MUTAGEN         475
FT                   /note="D->E: Decreased MPP(+) uptake, no change in MPP(+)
FT                   affinity. Decreased NMN uptake, increased NMN affinity.
FT                   Decreased choline uptake, increased choline affinity."
FT                   /evidence="ECO:0000269|PubMed:10570053"
FT   MUTAGEN         475
FT                   /note="D->N: Decreased MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:10570053"
FT   MUTAGEN         475
FT                   /note="D->R: Decreased MPP(+) uptake."
FT                   /evidence="ECO:0000269|PubMed:10570053"
FT   MUTAGEN         550
FT                   /note="T->A: No effect of PKC-induced stimulation on ASP
FT                   uptake. No effect of PKC-induced stimulation on ASP uptake;
FT                   when associated with A-286; A-292; A-296; A-328.
FT                   Significant increase of the ASP uptake by PKA activation.
FT                   No effect of PKA activation on ASP uptake; when associated
FT                   with A-286; A-292; A-296 and A-328. Significant reduction
FT                   of ASP uptake by p56(lck) tyrosine kinase-induced
FT                   inhibition. Significant reduction of ASP uptake by p56(lck)
FT                   tyrosine kinase-induced inhibition; when associated with A-
FT                   286; A-292; A-296; A-328. No significant effect on
FT                   trafficking from intracellular pools to the cell membrane;
FT                   when associated with A-286; A-292; A-296 and A-328.
FT                   suppresses phosphorylation by PKC; when associated with A-
FT                   286; A-292; A-296 and A-328."
FT                   /evidence="ECO:0000269|PubMed:15829703"
SQ   SEQUENCE   556 AA;  61541 MW;  9F42131CCCEC0920 CRC64;
     MPTVDDVLEQ VGEFGWFQKQ AFLLLCLISA SLAPIYVGIV FLGFTPGHYC QNPGVAELSQ
     RCGWSQAEEL NYTVPGLGPS DEASFLSQCM RYEVDWNQST LDCVDPLSSL VANRSQLPLG
     PCEHGWVYDT PGSSIVTEFN LVCGDAWKVD LFQSCVNLGF FLGSLVVGYI ADRFGRKLCL
     LVTTLVTSVS GVLTAVAPDY TSMLLFRLLQ GMVSKGSWVS GYTLITEFVG SGYRRTTAIL
     YQMAFTVGLV GLAGVAYAIP DWRWLQLAVS LPTFLFLLYY WFVPESPRWL LSQKRTTRAV
     RIMEQIAQKN GKVPPADLKM LCLEEDASEK RSPSFADLFR TPNLRKHTVI LMYLWFSCAV
     LYQGLIMHVG ATGANLYLDF FYSSLVEFPA AFIILVTIDR IGRIYPIAAS NLVTGAACLL
     MIFIPHELHW LNVTLACLGR MGATIVLQMV CLVNAELYPT FIRNLGMMVC SALCDLGGIF
     TPFMVFRLME VWQALPLILF GVLGLTAGAM TLLLPETKGV ALPETIEEAE NLGRRKSKAK
     ENTIYLQVQT GKSSST
//
